Allison G Hays1, Michael Schär2, Patricia Barditch-Crovo3, Shashwatee Bagchi4,5, Gabriele Bonanno1,2, Joseph Meyer1, Yohannes Afework2, Valerie Streeb1, Samuel Stradley1, Shannon Kelly1, Nicole M Anders6, Joseph B Margolick7, Shenghan Lai5,8, Gary Gerstenblith1, Robert G Weiss1,2. 1. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine. 2. Division of Magnetic Resonance Research, Department of Radiology, Johns Hopkins University School of Medicine. 3. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine. 4. Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. 6. Analytical Pharmacology Core, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine. 7. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health. 8. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Abstract
OBJECTIVES: People living with HIV (PWH) experience an increased burden of coronary artery disease (CAD) believed to be related, in part, to an interplay of chronically increased inflammation and traditional risk factors. Recent trials suggest cardiovascular benefits of the anti-inflammatory, colchicine, in HIV-seronegative CAD patients. However, the impact of colchicine on impaired vascular health, as measured by coronary endothelial function (CEF), an independent contributor to CAD, has not been studied in PWH. We tested the hypothesis that colchicine improves vascular health in PWH. DESIGN: This was a randomized, placebo-controlled, double-blinded trial in 81 PWH to test whether low-dose colchicine (0.6 mg daily) improves CEF over 8-24 weeks. METHODS: Coronary and systemic endothelial function and serum inflammatory markers were measured at baseline, and at 8 and 24 weeks. The primary endpoint was CEF, measured as the change in coronary blood flow from rest to that during an isometric handgrip exercise, an endothelial-dependent stressor, measured with non-invasive MRI at 8 weeks. RESULTS: Colchicine was well tolerated and not associated with increased adverse events. However, there were no significant improvements in coronary or systemic endothelial function or reductions in serum inflammatory markers at 8 or 24 weeks with colchicine as compared to placebo. CONCLUSIONS: In PWH with no history of CAD, low-dose colchicine was well tolerated but did not improve impaired coronary endothelial function, a predictor of cardiovascular events. These findings suggest that this anti-inflammatory approach using colchicine in PWH does not improve vascular health, the central, early driver of coronary atherosclerosis.
OBJECTIVES: People living with HIV (PWH) experience an increased burden of coronary artery disease (CAD) believed to be related, in part, to an interplay of chronically increased inflammation and traditional risk factors. Recent trials suggest cardiovascular benefits of the anti-inflammatory, colchicine, in HIV-seronegative CAD patients. However, the impact of colchicine on impaired vascular health, as measured by coronary endothelial function (CEF), an independent contributor to CAD, has not been studied in PWH. We tested the hypothesis that colchicine improves vascular health in PWH. DESIGN: This was a randomized, placebo-controlled, double-blinded trial in 81 PWH to test whether low-dose colchicine (0.6 mg daily) improves CEF over 8-24 weeks. METHODS: Coronary and systemic endothelial function and serum inflammatory markers were measured at baseline, and at 8 and 24 weeks. The primary endpoint was CEF, measured as the change in coronary blood flow from rest to that during an isometric handgrip exercise, an endothelial-dependent stressor, measured with non-invasive MRI at 8 weeks. RESULTS: Colchicine was well tolerated and not associated with increased adverse events. However, there were no significant improvements in coronary or systemic endothelial function or reductions in serum inflammatory markers at 8 or 24 weeks with colchicine as compared to placebo. CONCLUSIONS: In PWH with no history of CAD, low-dose colchicine was well tolerated but did not improve impaired coronary endothelial function, a predictor of cardiovascular events. These findings suggest that this anti-inflammatory approach using colchicine in PWH does not improve vascular health, the central, early driver of coronary atherosclerosis.
Authors: D Hürlimann; R Chenevard; F Ruschitzka; M Flepp; F Enseleit; M Béchir; R Kobza; J Muntwyler; B Ledergerber; T F Lüscher; G Noll; R Weber Journal: Heart Date: 2005-03-29 Impact factor: 5.994
Authors: Priscilla Y Hsue; Heather J Ribaudo; Steven G Deeks; Tanvir Bell; Paul M Ridker; Carl Fichtenbaum; Eric S Daar; Diane Havlir; Eunice Yeh; Ahmed Tawakol; Michael Lederman; Judith S Currier; James H Stein Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Allison G Hays; Glenn A Hirsch; Sebastian Kelle; Gary Gerstenblith; Robert G Weiss; Matthias Stuber Journal: J Am Coll Cardiol Date: 2010-11-09 Impact factor: 24.094
Authors: Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn Journal: N Engl J Med Date: 2017-08-27 Impact factor: 91.245
Authors: Janet Lo; Michael T Lu; Ezinne J Ihenachor; Jeffrey Wei; Sara E Looby; Kathleen V Fitch; Jinhee Oh; Chloe O Zimmerman; Janice Hwang; Suhny Abbara; Jorge Plutzky; Gregory Robbins; Ahmed Tawakol; Udo Hoffmann; Steven K Grinspoon Journal: Lancet HIV Date: 2015-01-09 Impact factor: 12.767
Authors: Michael Schär; Sahar Soleimanifard; Gabriele Bonanno; Jérôme Yerly; Allison G Hays; Robert G Weiss Journal: Magn Reson Med Date: 2018-07-19 Impact factor: 4.668
Authors: Stefan M Nidorf; Aernoud T L Fiolet; Arend Mosterd; John W Eikelboom; Astrid Schut; Tjerk S J Opstal; Salem H K The; Xiao-Fang Xu; Mark A Ireland; Timo Lenderink; Donald Latchem; Pieter Hoogslag; Anastazia Jerzewski; Peter Nierop; Alan Whelan; Randall Hendriks; Henk Swart; Jeroen Schaap; Aaf F M Kuijper; Maarten W J van Hessen; Pradyot Saklani; Isabel Tan; Angus G Thompson; Allison Morton; Chris Judkins; Willem A Bax; Maurits Dirksen; Marco Alings; Graeme J Hankey; Charley A Budgeon; Jan G P Tijssen; Jan H Cornel; Peter L Thompson Journal: N Engl J Med Date: 2020-08-31 Impact factor: 91.245
Authors: Francesca J Torriani; Lauren Komarow; Robert A Parker; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; James H Stein Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: Anum S Minhas; Erin Goerlich; Mary C Corretti; Armin Arbab-Zadeh; Sebastian Kelle; Thorsten Leucker; Amir Lerman; Allison G Hays Journal: Front Cardiovasc Med Date: 2022-04-15